CoChat

INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Hautamäki, Asta, Kivioja, Jarno, Vavuli, Satu, Kakko, Sakari, Savolainen, Eeva-Riitta, Savolainen, Markku J., Liinamaa, M. Johanna, Seitsonen, Sanna, Onkamo, Päivi, Järvelä, Irma, Immonen, Ilkka · 2013 · Retina
Cited by 35

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

In Brief Purpose: To study the association of single-nucleotide polymorphisms of interleukin 8, vascular endothelial growth factor, erythropoietin, complement factor H, complement component C3, and LOC387715 genes with the response to bevacizumab treatment in exudative age-related macular degeneration. Methods: Clinical records, smoking history, optical coherence tomography, and angiographies of 96 bevacizumab-treated exudative age-related macular degeneration patients were analyzed retrospectively. Blood DNA was collected. Based on the disappearance of intra- or subretinal fluid in optical coherence tomography, patients were graded as responders, partial responders, or nonresponders after 3 initial treatment visits and a median time of 3.5 months. Results: Interleukin 8 promoter polymorphism −251A/T was significantly associated with persisting fluid in optical coherence tomography. The A allele was more frequent in nonresponders than in responders (P = 0.033). In multivariate modeling, the AA genotype of −251A/T (P = 0.043) and occult (P = 0.042) or predominantly classic (P = 0.040) lesions predicted poorer outcome. Visual acuity change was better in responders than in nonresponders (P = 0.006). Baseline lesion size (P = 0.006) and retinal cysts after the treatment (P < 0.001) correlated with less visual acuity gain. Conclusion: The A allele and the homozygous AA genotype of interleukin 8 −251A/T were associated with anatomical nonresponse to bevacizumab treatment. The genotype AA of interleukin 8 promoter polymorphism −251A/T was associated with persisting intra- or subretinal fluid in exudative age-related macular degeneration patients after the initial treatment with intravitreal bevacizumab. Interleukin 8 seems to modulate the response to anti–vascular endothelial growth factor therapy at least during the first months of the .treatment

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e318285cf92

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 35

Metadata

Authors
Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E.-R., Savolainen, M. J., Liinamaa, M. J., Seitsonen, S., Onkamo, P., Järvelä, I., & Immonen, I.
Venue
Retina
Published
2013-10
Volume
33
Issue
9
Pages
1815-1827
ISSN
0275-004X (ISSN-L)
OpenAlex
W2075304664
Cited by
35
References
7
FWCI
4.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e318285cf92
The paper
Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E.-R., Savolainen, M. J., Liinamaa, M. J., Seitsonen, S., Onkamo, P., Järvelä, I., & Immonen, I. (2013). INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina. https://doi.org/10.1097/iae.0b013e318285cf92

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.